– UK Watford – Smith+Nephew (LON: SN | NYSE: SNN) today announced the appointment of Dr. Deepak Nath as the new CEO effective on 1 April 2022, succeeding Roland Diggelmann, who will step down on 31 March 2022.
“On behalf of the Board, I am delighted to welcome Deepak as Smith+Nephew’s incoming CEO. Deepak is a highly experienced leader with a track record of significant improvement in operations and execution at major global healthcare businesses. He is joining us at an inflection point for the business and will bring his drive, experience and expertise to lead the team in delivering our Strategy for Growth at pace,” said Board Chairman, Roberto Quarta.
About Dr. Deepak Nath
Deepak joins Smith+Nephew from Siemens Healthineers (2018-2022) where most recently he was President of the Diagnostics business segment responsible for $6 billion of sales and 15,000 employees. During his time there he led a major program to drive growth and margin expansion through improved execution and a strong results-focused culture.
Before Siemens Healthineers, Deepak held several senior roles at Abbott Laboratories Inc (2007-2017) spanning R&D, marketing, commercial and divisional leadership, rising to become President of Abbott Vascular and an Executive Officer of Abbott Laboratories. At Abbott, he significantly improved the performance of the Vascular business and had a leadership role in the $28 billion acquisition of St Jude Medical.
Deepak also worked for Amgen (2004-2007), McKinsey and Company (2000-2004), and as a scientist at the Lawrence Livermore National Laboratory. He holds BSc and MSc degrees in Mechanical Engineering and a Ph.D. in Theoretical Mechanics from the University of California, Berkeley.
Deepak Nath said: “Smith+Nephew is a great company with innovation at its core and a purpose of Life Unlimited, supporting patients around the world in returning to a healthy and fulfilled life. I am honoured to have been given the opportunity to lead the business. I look forward to building on Smith+Nephew’s rich history and heritage and working with the team to take it to the next level of growth.”
Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration, and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
Founded in Hull, UK, in 1856, we now operate in more than 100 countries and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100. The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries unless the context requires otherwise.
For more information: https://www.smith-nephew.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.